Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 9/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.45 |
| ▸ | MAPT | P10636 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TNFRSF1A | P19438 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8034332 | 0.82 | MAOB (0.48) | MAOBMEN1KMT2AMAPTKDM4E | |
| SCHEMBL3680495 | 0.82 | ERN1 (0.52) | MAOBMEN1KMT2AMAPTKDM4E | |
| SCHEMBL13351480 | 0.81 | MAOB (0.50) | MAOBMEN1KMT2AMAPTKDM4E | |
| SCHEMBL13318665 | 0.77 | LTA4H (0.44) | MAOBMEN1KMT2AMAPTKDM4E | |
| SCHEMBL3690457 | 0.75 | MEN1 (0.66) | MAOBMEN1KMT2AMAPTKDM4E | |
| SCHEMBL10072606 | 0.75 | MAOB (0.52) | MAOBMEN1KMT2AMAPTKDM4E | |
| SCHEMBL13318681 | 0.75 | GABRA1 (0.41) | KMT2AKDM4ERAB9ASMN1; SMN2NPC1 | |
| SCHEMBL7918305 | 0.75 | MAOB (0.42) | MAOBMEN1KMT2AMAPTKDM4E | |
| SCHEMBL8381118 | 0.75 | MAPT (0.44) | MAOBMEN1KMT2AMAPTKDM4E | |
| SCHEMBL28476825 | 0.74 | MAOB (0.51) | MAOBMEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8426360-B2 | Carbocyclic oxime hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426360-B2 | Carbocyclic oxime hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8361958-B2 | Oximyl HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361958-B2 | Oximyl HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-7728148-B2 | Acyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728148-B2 | Acyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090197888-A1 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197888-A1 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090149491-A1 | CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090149491-A1 | CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | MAOB 400/4885MEN1 4620/4885KMT2A 2022/4885 |
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | DPP4, PREP, PEPD | MAOB 679/4885MEN1 4522/4885KMT2A 2390/4885 |
| US-20090197888-A1 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | CTSC, PRSS1, SPINT2 | MAOB 2465/4885MEN1 3935/4885KMT2A 2768/4885 |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | MAOB 480/4885MEN1 4811/4885KMT2A 2543/4885 |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | MAOB 400/4885MEN1 4620/4885KMT2A 2022/4885 |
| US-20090149491-A1 | CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | CCNE2, CYP4A22, CCNE1 | MAOB 490/4885MEN1 4687/4885KMT2A 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.